{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:27:37Z","timestamp":1773073657698,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T00:00:00Z","timestamp":1521504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00520-018-4137-x","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T17:00:34Z","timestamp":1521565234000},"page":"2075-2090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Patient-reported outcomes in relapsed\/refractory multiple myeloma: a systematic review"],"prefix":"10.1007","volume":"26","author":[{"given":"Francesco","family":"Sparano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Niscola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Caravita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Efficace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,20]]},"reference":[{"key":"4137_CR1","doi-asserted-by":"publisher","unstructured":"Mols F, Oerlemans S, Vos AH, Koster A, Verelst S, Sonneveld P, van de Poll-Franse LV (2012) Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry. Eur J Haematol 89 (4):311\u2013319. doi:\n                    https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01831.x","DOI":"10.1111\/j.1600-0609.2012.01831.x"},{"issue":"12","key":"4137_CR2","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1002\/sim.4780101207","volume":"10","author":"M Schumacher","year":"1991","unstructured":"Schumacher M, Olschewski M, Schulgen G (1991) Assessment of quality of life in clinical trials. Stat Med 10(12):1915\u20131930","journal-title":"Stat Med"},{"key":"4137_CR3","unstructured":"US Food and Drug Administration: Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. US Department of Health and Human Services Food and Drug Administration.December 2009. \n                    http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf\n                    \n                  . Accessed April 29, 2016"},{"issue":"Suppl. 1","key":"4137_CR4","first-page":"5","volume":"4","author":"S Kurtin","year":"2013","unstructured":"Kurtin S (2013) Relapsed or relapsed\/refractory multiple myeloma. Journal of the Advanced Practitioner in Oncology 4(Suppl. 1):5\u201314","journal-title":"Journal of the Advanced Practitioner in Oncology"},{"issue":"5","key":"4137_CR5","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516\u20132520. \n                    https:\/\/doi.org\/10.1182\/blood-2007-10-116129","journal-title":"Blood"},{"issue":"24","key":"4137_CR6","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1200\/JCO.2014.55.1028","volume":"32","author":"TM Wildes","year":"2014","unstructured":"Wildes TM, Rosko A, Tuchman SA (2014) Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol 32(24):2531\u20132540","journal-title":"J Clin Oncol"},{"issue":"5","key":"4137_CR7","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","volume":"111","author":"H Brenner","year":"2008","unstructured":"Brenner H, Gondos A, Pulte D (2008) Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111(5):2521\u20132526. \n                    https:\/\/doi.org\/10.1182\/blood-2007-08-104984","journal-title":"Blood"},{"issue":"1","key":"4137_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejca.2009.07.006","volume":"46","author":"M Schaapveld","year":"2010","unstructured":"Schaapveld M, Visser O, Siesling S, Schaar CG, Zweegman S, Vellenga E (2010) Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer 46(1):160\u2013169. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2009.07.006","journal-title":"Eur J Cancer"},{"issue":"9","key":"4137_CR9","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906\u2013917. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0801479","journal-title":"N Engl J Med"},{"issue":"19","key":"4137_CR10","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jedrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Blade J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA (2012) Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366(19):1759\u20131769. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1112704","journal-title":"N Engl J Med"},{"issue":"5","key":"4137_CR11","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","volume":"118","author":"PM Fayers","year":"2011","unstructured":"Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksac M, Bringhen S, Mary JY, Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I, Musto P, Benboubker L, Schaafsma M, Sonneveld P, Facon T (2011) Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118(5):1239\u20131247. \n                    https:\/\/doi.org\/10.1182\/blood-2011-03-341669","journal-title":"Blood"},{"issue":"5","key":"4137_CR12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/leu.2015.356","volume":"30","author":"J Laubach","year":"2016","unstructured":"Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG (2016) Management of relapsed multiple myeloma: recommendations of the international myeloma working group. Leukemia 30(5):1005\u20131017. \n                    https:\/\/doi.org\/10.1038\/leu.2015.356","journal-title":"Leukemia"},{"issue":"4","key":"4137_CR13","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3324\/haematol.2015.129189","volume":"101","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Broijl A (2016) Treatment of relapsed and refractory multiple myeloma. Haematologica 101(4):396\u2013406. \n                    https:\/\/doi.org\/10.3324\/haematol.2015.129189","journal-title":"Haematologica"},{"issue":"2","key":"4137_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/sj.leu.2405016","volume":"22","author":"KC Anderson","year":"2008","unstructured":"Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P (2008) Clinically relevant end points and new drug approvals for myeloma. Leukemia 22(2):231\u2013239. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2405016","journal-title":"Leukemia"},{"issue":"19","key":"4137_CR15","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1182\/blood-2015-05-612960","volume":"126","author":"A Larocca","year":"2015","unstructured":"Larocca A, Palumbo A (2015) How I treat fragile myeloma patients. Blood 126(19):2179\u20132185. \n                    https:\/\/doi.org\/10.1182\/blood-2015-05-612960","journal-title":"Blood"},{"issue":"6","key":"4137_CR16","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3324\/haematol.2012.075051","volume":"98","author":"S Bringhen","year":"2013","unstructured":"Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D, Cavalli M, Wijermans P, Ria R, Offidani M, Lahuerta JJ, Liberati AM, Mina R, Callea V, Schaafsma M, Cerrato C, Marasca R, Franceschini L, Evangelista A, Teruel AI, van der Holt B, Montefusco V, Ciccone G, Boccadoro M, San Miguel J, Sonneveld P, Palumbo A (2013) Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica 98(6):980\u2013987. \n                    https:\/\/doi.org\/10.3324\/haematol.2012.075051","journal-title":"Haematologica"},{"issue":"1","key":"4137_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Blade J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26(1):149\u2013157","journal-title":"Leukemia"},{"key":"4137_CR18","doi-asserted-by":"publisher","first-page":"j878","DOI":"10.1136\/bmj.j878","volume":"356","author":"SA Murray","year":"2017","unstructured":"Murray SA, Kendall M, Mitchell G, Moine S, Amblas-Novellas J, Boyd K (2017) Palliative care from diagnosis to death. BMJ 356:j878","journal-title":"BMJ"},{"issue":"10","key":"4137_CR19","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/leu.2013.185","volume":"27","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld P, Verelst SG, Lewis P, Gray-Schopfer V, Hutchings A, Nixon A, Petrucci MT (2013) Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia 27(10):1959\u20131969. \n                    https:\/\/doi.org\/10.1038\/leu.2013.185","journal-title":"Leukemia"},{"issue":"4","key":"4137_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1600-0609.2009.01303.x","volume":"83","author":"AK Kvam","year":"2009","unstructured":"Kvam AK, Fayers P, Hjermstad M, Gulbrandsen N, Wisloff F (2009) Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur J Haematol 83(4):279\u2013289","journal-title":"Eur J Haematol"},{"issue":"5","key":"4137_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"4137_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejh.12882","volume":"99","author":"LK Nielsen","year":"2017","unstructured":"Nielsen LK, Jarden M, Andersen CL, Frederiksen H, Abildgaard N (2017) A systematic review of health-related quality of life in longitudinal studies of myeloma patients. Eur J Haematol 99:3\u201317. \n                    https:\/\/doi.org\/10.1111\/ejh.12882","journal-title":"Eur J Haematol"},{"issue":"6","key":"4137_CR23","first-page":"858","volume":"90","author":"A Palumbo","year":"2005","unstructured":"Palumbo A, Petrucci MT, Lauta VM, Musto P, Caravita T, Barbui AM, Nunzi M, Boccadoro M (2005) Correlation between fatigue and hemoglobin level in multiple myeloma patients: results of a cross-sectional study. Haematologica 90(6):858\u2013860","journal-title":"Haematologica"},{"issue":"4","key":"4137_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1600-0609.2009.01404.x","volume":"84","author":"AK Kvam","year":"2010","unstructured":"Kvam AK, Fayers P, Wisloff F (2010) What changes in health-related quality of life matter to multiple myeloma patients? A prospective study. Eur J Haematol 84(4):345\u2013353. \n                    https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01404.x","journal-title":"Eur J Haematol"},{"issue":"5","key":"4137_CR25","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpainsymman.2012.11.003","volume":"46","author":"E Boland","year":"2013","unstructured":"Boland E, Eiser C, Ezaydi Y, Greenfield DM, Ahmedzai SH, Snowden JA (2013) Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. J Pain Symptom Manag 46(5):671\u2013680. \n                    https:\/\/doi.org\/10.1016\/j.jpainsymman.2012.11.003","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"4137_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00520-013-1991-4","volume":"22","author":"K Jordan","year":"2014","unstructured":"Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, Kyriakou C, Williams CD, Peters S, Davies FE (2014) Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer 22(2):417\u2013426. \n                    https:\/\/doi.org\/10.1007\/s00520-013-1991-4","journal-title":"Support Care Cancer"},{"key":"4137_CR27","doi-asserted-by":"publisher","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6 (7):e1000097. doi:\n                    https:\/\/doi.org\/10.1371\/journal.pmed.1000097","DOI":"10.1371\/journal.pmed.1000097"},{"issue":"2","key":"4137_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142\u2013152. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1411321","journal-title":"N Engl J Med"},{"key":"4137_CR29","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2016.66.9648","volume":"34","author":"AK Stewart","year":"2016","unstructured":"Stewart AK, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A (2016) Health-related quality of life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol 34:3921\u20133930. \n                    https:\/\/doi.org\/10.1200\/jco.2016.66.9648","journal-title":"J Clin Oncol"},{"issue":"9","key":"4137_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.clml.2015.05.007","volume":"15","author":"K Weisel","year":"2015","unstructured":"Weisel K, Dimopoulos M, Song KW, Moreau P, Palumbo A, Belch A, Schey S, Sonneveld P, Sternas L, Yu X, Amatya R, Gibson CJ, Zaki M, Jacques C, San Miguel J (2015) Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed\/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III trial. Clin Lymphoma Myeloma Leuk 15(9):519\u2013530. \n                    https:\/\/doi.org\/10.1016\/j.clml.2015.05.007","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4137_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3324\/haematol.2014.112557","volume":"2","author":"KW Song","year":"2015","unstructured":"Song KW, Dimopoulos MA, Weisel KC, Moreau P, Palumbo A, Belch A, Schey S, Sonneveld P, Sternas L, Yu X, Amatya R, Monzini MS, Zaki M, Jacques C, Miguel JS (2015) Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and\/or refractory multiple myeloma. Haematologica 2:63\u201367. \n                    https:\/\/doi.org\/10.3324\/haematol.2014.112557","journal-title":"Haematologica"},{"issue":"11","key":"4137_CR32","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"J San Miguel","year":"2013","unstructured":"San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. The Lancet Oncology 14(11):1055\u20131066. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(13)70380-2","journal-title":"The Lancet Oncology"},{"issue":"20","key":"4137_CR33","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/blood-2014-11-568923","volume":"125","author":"AK Nooka","year":"2015","unstructured":"Nooka AK, Kastritis E, Dimopoulos MA, Lonial S (2015) Treatment options for relapsed and refractory multiple myeloma. Blood 125(20):3085\u20133099 doi:blood-2014-11-568923 [pii]","journal-title":"Blood"},{"key":"4137_CR34","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1365-2141.2008.07378.x","volume":"4","author":"SJ Lee","year":"2008","unstructured":"Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, Crawford B, Massaro J, Dhawan R, Gupta S, Anderson KC (2008) Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol 4:511\u2013519. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07378.x","journal-title":"Br J Haematol"},{"issue":"24","key":"4137_CR35","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487\u20132498. \n                    https:\/\/doi.org\/10.1056\/NEJMoa043445","journal-title":"N Engl J Med"},{"issue":"5","key":"4137_CR36","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1365-2141.2007.06585.x","volume":"137","author":"PG Richardson","year":"2007","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC (2007) Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 137(5):429\u2013435. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06585.x","journal-title":"Br J Haematol"},{"issue":"6","key":"4137_CR37","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1200\/JCO.2005.04.0824","volume":"24","author":"D Dubois","year":"2006","unstructured":"Dubois D, Dhawan R, van de Velde H, Esseltine D, Gupta S, Viala M, de la Loge C (2006) Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol 24(6):976\u2013982. \n                    https:\/\/doi.org\/10.1200\/jco.2005.04.0824","journal-title":"J Clin Oncol"},{"issue":"7","key":"4137_CR38","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jclinepi.2006.10.006","volume":"60","author":"M Viala","year":"2007","unstructured":"Viala M, Bhakar AL, de la Loge C, van de Velde H, Esseltine D, Chang M, Dhawan R, Dubois D (2007) Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis. J Clin Epidemiol 60(7):670\u2013679. \n                    https:\/\/doi.org\/10.1016\/j.jclinepi.2006.10.006","journal-title":"J Clin Epidemiol"},{"issue":"26","key":"4137_CR39","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609\u20132617. \n                    https:\/\/doi.org\/10.1056\/NEJMoa030288","journal-title":"N Engl J Med"},{"issue":"6","key":"4137_CR40","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1600-0609.2012.01775.x","volume":"88","author":"M Hjorth","year":"2012","unstructured":"Hjorth M, Hjertner \u00d8, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andr\u00e9asson B, Billstr\u00f6m R, Carlson K, Carlsson MS, Flogeg\u00e5rd M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othz\u00e9n A, Swedin A (2012) Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol 88(6):485\u2013496. \n                    https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01775.x","journal-title":"Eur J Haematol"},{"key":"4137_CR41","doi-asserted-by":"crossref","unstructured":"Waage A, Gimsing P, Juliusson G, Turesson I, Gulbrandsen N, Eriksson T, Hjorth M, Nielsen JL, Lenhoff S, Westin J, Wisloff F (2004) Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematol 125(2):149\u2013155. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.04879.x [doi]","DOI":"10.1111\/j.1365-2141.2004.04879.x"},{"issue":"17","key":"4137_CR42","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG (2016) Oral Ixazomib, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621\u20131634. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1516282","journal-title":"N Engl J Med"},{"issue":"7","key":"4137_CR43","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Rollig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373(7):621\u2013631. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1505654","journal-title":"N Engl J Med"},{"key":"4137_CR44","doi-asserted-by":"crossref","unstructured":"Alegre A, Oriol-Rocafiguera A, Garcia-Larana J, Mateos MV, Sureda A, Martinez-Chamorro C, Cibeira MT, Aguado B, Knight R, Rosettani B (2012) Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. Leuk Lymphoma 53(9):1714\u20131721. https:\/\/doi.org\/10.3109\/10428194.2012.662643 [doi]","DOI":"10.3109\/10428194.2012.662643"},{"issue":"3","key":"4137_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.20","volume":"7","author":"X Leleu","year":"2017","unstructured":"Leleu X, Kyriakou C, Vande Broek I, Murphy P, Bacon P, Lewis P, Gilet H, Arnould B, Petrucci MT (2017) Prospective longitudinal study on quality of life in relapsed\/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment. Blood Cancer J 7(3):e543. \n                    https:\/\/doi.org\/10.1038\/bcj.2017.20","journal-title":"Blood Cancer J"},{"key":"4137_CR46","doi-asserted-by":"crossref","unstructured":"Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, Go R, Hegeman R, Longo W, Williams E, Asimakopoulos F, Miyamoto S (2014) Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol 74(4):875\u2013882. https:\/\/doi.org\/10.1007\/s00280-014-2550-5 [doi]","DOI":"10.1007\/s00280-014-2550-5"},{"issue":"11","key":"4137_CR47","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","volume":"43","author":"K Cocks","year":"2007","unstructured":"Cocks K, Cohen D, Wisloff F, Sezer O, Lee S, Hippe E, Gimsing P, Turesson I, Hajek R, Smith A, Graham L, Phillips A, Stead M, Velikova G, Brown J (2007) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 43(11):1670\u20131678","journal-title":"Eur J Cancer"},{"issue":"6","key":"4137_CR48","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1525-1438.2003.13603.x","volume":"13","author":"EA Calhoun","year":"2003","unstructured":"Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, Cella D (2003) Psychometric evaluation of the functional assessment of cancer therapy\/gynecologic oncology group-neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13(6):741\u2013748","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"4137_CR49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manag 13(2):63\u201374","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"4137_CR50","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1017\/S0266462312000086","volume":"28","author":"A Morrison","year":"2012","unstructured":"Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, Mierzwinski-Urban M, Clifford T, Hutton B, Rabb D (2012) The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care 28(2):138\u2013144. \n                    https:\/\/doi.org\/10.1017\/s0266462312000086","journal-title":"Int J Technol Assess Health Care"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4137-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4137-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4137-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T20:22:11Z","timestamp":1553026931000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4137-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,20]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["4137"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4137-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,20]]},"assertion":[{"value":"28 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FE: Research funding (Lundbeck, TEVA and Amgen); Consultant\/Advisory Role (Bristol-Myers Squibb, Seattle Genetics, TEVA and Incyte)MC: Remuneration (Janssen, Celgene, Amgen, Takeda, Bristol-Myers Squibb), Consultant\/Advisory Role (Janssen, Celgene, Amgen, Takeda, Bristol-Myers Squibb)TC: Consultant\/Advisory Role (Janssen-Cilag, Celgene, Amgen, Takeda, Bristol-Myers Squibb)The remaining authors have no conflicts of interest.I have full control of all primary data and I agree to allow the journal to review their data if requested.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}